有助于生殖技术的怀孕是否更有可能接触到产药物? 一个全人口研究的研究
Anna Kemp-Casey1, Roger Hart2, Elizabeth Milne3
1Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Adelaide, South Australia, Australia.
The Australian & New Zealand journal of obstetrics & gynaecology
|December 9, 2024
概括
通过辅助生殖技术 (ART) 怀孕的孕妇与其他受孕方法相比,暴露于产性药物更高. 这可能会导致ART婴儿出生缺陷风险增加.
科学领域:
- 生殖医学 生殖医学
- 药学流行病学 药学流行病学
- 产科 产科 产科 产科 产科
背景情况:
- 辅助生殖技术 (ART) 怀孕有更高的出生缺陷风险.
- 潜在的原因,比如对原药物的暴露,在ART和非ART怀孕之间没有很好的比较.
研究的目的:
- 为了比较不同的受孕方法中产性药物暴露的流行率.
- 研究的ART,排卵诱导 (OI),不孕期和自然怀孕.
主要方法:
- 链接西澳大利亚出生数据集 (2012-2014) 对于活产和死产.
- 治疗产品协会D/X类药物暴露的计算流行率,按季度和受孕组划分.
主要成果:
- 总体上,D/X类药物暴露率低 (<1%).
- 在ART和OI怀孕中,与非生育和生育组相比,在第一和后三个月中,对D类药物的暴露率更高.
- 在所有组和三个月中,X类药物暴露率为<0.5%.
结论:
- 虽然总体上原性药物暴露率很低,但在ART怀孕中暴露率最高.
- 这种较高的暴露可能是导致ART怀孕婴儿中出生缺陷率较高的因素.
相关概念视频
Teratogenicity
2.3K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.3K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
120
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
120


